Literature DB >> 15480815

Treatment of cancer-related pain with transdermal buprenorphine: a report of three cases.

Paul Schriek1.   

Abstract

Three patients suffering from pain arising from renal and metastasing prostate and breast cancer were successfully treated with transdermal buprenorphine. The three cases demonstrate that transdermal buprenorphine is an easy-to-use and effective therapeutic option for the treatment of advanced cancer pain, that it can also be used in opioid rotation as an alternative after formerly applied steps II or III opioids have failed and that long-term treatment without dose escalation or compromise in tolerability is possible.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15480815     DOI： 10.1007/s00520-004-0695-1

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN： 0941-4355            Impact factor:   3.603


  9 in total

1.  Old dog--new (ma)trix.

Authors:  K Budd; B J Collett
Journal:  Br J Anaesth       Date:  2003-06       Impact factor: 9.166

Review 2.  Treatment of cancer pain with transdermal fentanyl.

Authors:  G K Gourlay
Journal:  Lancet Oncol       Date:  2001-03       Impact factor: 41.316

Review 3.  Buprenorphine TDS: the clinical development rationale and results.

Authors:  Lukas Radbruch; Ans Vielvoye-Kerkmeer
Journal:  Int J Clin Pract Suppl       Date:  2003-02

Review 4.  Buprenorphine and the transdermal system: the ideal match in pain management.

Authors:  Keith Budd
Journal:  Int J Clin Pract Suppl       Date:  2003-02

5.  Buprenorphine in a transdermal therapeutic system--a new option.

Authors:  K Böhme
Journal:  Clin Rheumatol       Date:  2002-02       Impact factor: 2.980

Review 6.  Buprenorphine: a review of its pharmacological properties and therapeutic efficacy.

Authors:  R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1979-02       Impact factor: 9.546

7.  Validation of World Health Organization Guidelines for cancer pain relief: a 10-year prospective study.

Authors:  Detlev F J Zech; Stefan Grond; John Lynch; Dagmar Hertel; Klaus A Lehmann
Journal:  Pain       Date:  1995-10       Impact factor: 6.961

8.  Transdermal fentanyl for the management of cancer pain: a survey of 1005 patients.

Authors:  L Radbruch; R Sabatowski; F Petzke; A Brunsch-Radbruch; S Grond; K A Lehmann
Journal:  Palliat Med       Date:  2001-07       Impact factor: 4.762

9.  Analgesic efficacy and tolerability of transdermal buprenorphine in patients with inadequately controlled chronic pain related to cancer and other disorders: a multicenter, randomized, double-blind, placebo-controlled trial.

Authors:  Reinhard Sittl; Norbert Griessinger; Rudolf Likar
Journal:  Clin Ther       Date:  2003-01       Impact factor: 3.393
  9 in total
  4 in total

Review 1.  Buprenorphine in cancer pain.

Authors:  Mellar P Davis
Journal:  Support Care Cancer       Date:  2005-07-12       Impact factor: 3.603

2.  Is there a ceiling effect of transdermal buprenorphine? Preliminary data in cancer patients.

Authors:  Sebastiano Mercadante; Patrizia Ferrera; Patrizia Villari
Journal:  Support Care Cancer       Date:  2006-11-15       Impact factor: 3.359

Review 3.  Toward a systematic approach to opioid rotation.

Authors:  Howard S Smith; John F Peppin
Journal:  J Pain Res       Date:  2014-10-17       Impact factor: 3.133

4.  Transdermal buprenorphine in the management of persistent pain - safety aspects.

Authors:  Rudolf Likar
Journal:  Ther Clin Risk Manag       Date:  2006-03       Impact factor: 2.423
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.